InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the complete record of transactions filed by HIGGINS JOHN L, Chairman & CEO. Officer active across 2 companies, notably Ligand Pharmaceuticals INC. In total, 12 filings have been recorded. Total volume traded: €841k. The latest transaction was disclosed on 10 June 2022 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations12 total
020,423 shares0
Common Stock
SEC:0000886163-22-000091:0·
€62,5311,000 shares@ €62.53140.0009% mcap100.0% of flow
Common Stock
SEC:0001415889-22-006392:0·
€165,9698,000 shares@ €20.74620.0044% mcap13.2% of flow
Common Stock
SEC:0000886163-22-000060:0·
€212,8731,946 shares@ €109.390.0057% mcap17.0% of flow
Common Stock
SEC:0000886163-22-000022:0·
09,606 shares0
Common Stock
SEC:0000886163-22-000013:0·
09,606 shares0
Common Stock
SEC:0000886163-22-000013·
€420,4943,000 shares@ €140.16460.011% mcap95.9% of flow
Common Stock
SEC:0000886163-21-000134·
€420,4943,000 shares@ €140.16460.011% mcap33.5% of flow
Common Stock
SEC:0000886163-21-000134:0·
0194 shares0
Common Stock
SEC:0000914190-21-000399·
0194 shares0
Common Stock
SEC:0000914190-21-000399:0·
€17,897247 shares@ €72.45610.0005% mcap4.1% of flow
Common Stock
SEC:0000886163-21-000098·
€17,897247 shares@ €72.45610.0005% mcap1.4% of flow
Common Stock
SEC:0000886163-21-000098:0·
12 of 12 declarations
About HIGGINS JOHN L
John L. Higgins is the Chief Executive Officer and Director of Ligand Pharmaceuticals Inc and Bio-Techne Corp. In these roles, he is responsible for the strategic direction of the companies and the management of their operations. Higgins plays a key role in developing growth initiatives and implementing the companies' vision. His leadership and expertise in the biopharmaceutical sector strengthen Ligand and Bio-Techne's market position.
